Literature DB >> 17465267

Prognostic impact of haemoglobin levels in breast cancer.

Daniel Ulrich Boehm1, Antje Lebrecht, Marcus Schmidt, Wulf Siggelkow, Christine Lindner, Antonia Litz, Eva Ulbrich, Heinz Koelbl.   

Abstract

BACKGROUND: Many patients with solid tumours suffer from anaemia, as a consequence of the disease itself or its treatment. Anaemia affects the quality of life and can have a negative impact on overall survival. The aim of the current study was to analyse the impact of haemoglobin levels on the prognosis of patients with primary breast cancer. PATIENTS AND METHODS: Retrospective data from 249 women treated for operable breast tumours were included in our study. Haemoglobin (Hb) levels independently of anticancer therapy were compared for the prognostic influence on disease-free and overall survival.
RESULTS: A significant correlation between higher minimum Hb level during chemotherapy and the disease-free and overall survival was found. Pre-treatment haemoglobin levels had no prognostic influence on the disease-free and overall survival.
CONCLUSION: The present data showed that anaemia during adjuvant chemotherapy to be a negative prognostic indicator for survival of patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465267

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Effect of vascular haemoglobin concentrations on ultrasound-guided diffuse optical tomography in differentiating benign from malignant breast lesions.

Authors:  Ning Lv; Ni He; Yaopan Wu; Chuanmiao Xie; Yue Wang; Yanan Kong; Weidong Wei; Peihong Wu
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

2.  Prediction of outcome in breast cancer patients using test parameters from complete blood count.

Authors:  Pingping Zhang; Yulong Zong; Mohan Liu; Yanhong Tai; Yuan Cao; Chengiin Hu
Journal:  Mol Clin Oncol       Date:  2016-03-22

3.  Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.

Authors:  Wenjie Zhu; Binghe Xu
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

4.  Impact of preoperative anemia on relapse and survival in breast cancer patients.

Authors:  YingJun Zhang; YuYang Chen; DongTai Chen; Yu Jiang; Wan Huang; HanDong Ouyang; Wei Xing; MuSheng Zeng; XiaoMing Xie; Weian Zeng
Journal:  BMC Cancer       Date:  2014-11-18       Impact factor: 4.430

5.  Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer.

Authors:  Bo Chen; Danian Dai; Hailin Tang; Xiaohong Ai; Xi Chen; Xiaoyan Zhang; Zhiyan Li; Xiaoming Xie
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

6.  Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer.

Authors:  Chia-Lin Lee; Chun-Hao Tsai; Dah-Cherng Yeh; Chi-Shy Lin; Yu-Fen Li; Huey-En Tzeng
Journal:  Oncotarget       Date:  2017-01-03

7.  Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.

Authors:  Kenichi Inoue; Masato Takahashi; Hirofumi Mukai; Takashi Yamanaka; Chiyomi Egawa; Yukinori Sakata; Hiroki Ikezawa; Toshiyuki Matsuoka; Junji Tsurutani
Journal:  Invest New Drugs       Date:  2020-01-16       Impact factor: 3.850

8.  Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).

Authors:  Shengyu Pu; Ke Wang; Yang Liu; Xiaoqin Liao; Heyan Chen; Jianjun He; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-19       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.